AM-630 (6-Iodopravadoline) is a drug that acts as a potent and selective inverse agonist for the cannabinoid receptor CB2, with a Ki of 32.1nM at CB2 and 165x selectivity over CB1, at which it acted as a weak partial agonist.[1][2] It is used in the study of CB2 mediated responses and has been used to investigate the possible role of CB2 receptors in the brain.[3][4] AM-630 is significant as one of the first indole derived cannabinoid ligands substituted on the 6-position of the indole ring, a position that has subsequently been found to be important in determining affinity and efficacy at both the CB1 and CB2 receptors, and has led to the development of a large number of related derivatives.[5][6][7][8][9]
[edit] See also
[edit] References
- ^ Ross RA, et al. (February 1999). "Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656, and AM630". British Journal of Pharmacology 126 (3): 665–72. doi:10.1038/sj.bjp.0702351. PMC 1565857. PMID 10188977. //www.ncbi.nlm.nih.gov/pmc/articles/PMC1565857/.
- ^ Murataeva, N.; MacKie, K.; Straiker, A. (2012). "The CB2-preferring agonist JWH015 also potently and efficaciously activates CB1 in autaptic hippocampal neurons". Pharmacological Research 66 (5): 437. doi:10.1016/j.phrs.2012.08.002. PMID 22921769. edit
- ^ Morgan NH, Stanford IM, Woodhall GL (September 2009). "Functional CB2 type cannabinoid receptors at CNS synapses". Neuropharmacology 57 (4): 356–68. doi:10.1016/j.neuropharm.2009.07.017. PMID 19616018.
- ^ Ishiguro H, et al. (May 2010). "Brain cannabinoid CB2 receptor in schizophrenia". Biological Psychiatry 67 (10): 974–82. doi:10.1016/j.biopsych.2009.09.024. PMID 19931854.
- ^ Eissenstat, M. A.. et al. (1995). "Aminoalkylindoles: Structure-Activity Relationships of Novel Cannabinoid Mimetics". Journal of Medicinal Chemistry 38 (16): 3094. doi:10.1021/jm00016a013. PMID 7636873. edit
- ^ Hongfeng Deng. Design and synthesis of selective cannabinoid receptor ligands: Aminoalkylindole and other heterocyclic analogs. PhD Dissertation, University of Connecticut, 2000.
- ^ Hynes J, et al. (September 2002). "C-3 Amido-indole cannabinoid receptor modulators". Bioorganic & Medicinal Chemistry Letters 12 (17): 2399–402. doi:10.1016/S0960-894X(02)00466-3. PMID 12161142.
- ^ Frost, J. M., et al. (2008). "Indol-3-yl-tetramethylcyclopropyl Ketones: Effects of Indole Ring Substitution on CB2 Cannabinoid Receptor Activity". Journal of Medicinal Chemistry 51 (6): 1904. doi:10.1021/jm7011613. PMID 18311894. edit
- ^ Adam, J. M., et al. (2010). "Design, synthesis, and structure–activity relationships of indole-3-carboxamides as novel water soluble cannabinoid CB1 receptor agonists". MedChemComm 1: 54. doi:10.1039/c0md00022a. edit
|
|
|
| Phytocannabinoids |
|
|
| Cannabinoid metabolites |
|
|
| Endogenous cannabinoids |
|
|
Synthetic cannabinoid
receptor agonists |
Classical cannabinoids
(Dibenzopyrans) |
|
|
| Nonclassical cannabinoids |
|
|
| Benzoylindoles |
|
|
| Naphthoylindoles |
|
|
| Naphthylmethylindoles |
|
|
| Phenylacetylindoles |
|
|
| Naphthoylpyrroles |
|
|
| Eicosanoids |
|
|
| Others |
|
|
|
Allosteric modulators of
cannabinoid receptors |
|
|
Endocannabinoid
activity enhancers |
|
|
Cannabinoid receptor
antagonists and
inverse agonists |
|
|
(what is this?) (verify)
